Pharma Mar, S.A.
PHMMF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $41,850 | $56,392 | $38,858 | $48,362 |
| % Growth | -25.8% | 45.1% | -19.7% | – |
| Cost of Goods Sold | $5,062 | $2,781 | $3,401 | $1,313 |
| Gross Profit | $36,787 | $53,611 | $35,457 | $47,049 |
| % Margin | 87.9% | 95.1% | 91.2% | 97.3% |
| R&D Expenses | $25,966 | $26,178 | $21,293 | $27,522 |
| G&A Expenses | $0 | $7,311 | $7,519 | -$20,231 |
| SG&A Expenses | $13,720 | $14,685 | $13,684 | -$36,626 |
| Sales & Mktg Exp. | $0 | $7,374 | $6,165 | -$16,395 |
| Other Operating Expenses | $4,341 | -$11,403 | $3,565 | $51,260 |
| Operating Expenses | $44,026 | $29,460 | $38,542 | $42,156 |
| Operating Income | -$7,239 | $24,151 | -$3,085 | $4,893 |
| % Margin | -17.3% | 42.8% | -7.9% | 10.1% |
| Other Income/Exp. Net | $2,456 | -$799 | -$819 | $4,652 |
| Pre-Tax Income | -$4,783 | $23,352 | -$3,904 | $9,545 |
| Tax Expense | $28 | -$18 | $45 | -$9,139 |
| Net Income | -$4,811 | $23,370 | -$3,949 | $18,684 |
| % Margin | -11.5% | 41.4% | -10.2% | 38.6% |
| EPS | -0.28 | 1.35 | -0.23 | 1.06 |
| % Growth | -120.7% | 687% | -121.7% | – |
| EPS Diluted | -0.28 | 1.35 | -0.23 | 1.06 |
| Weighted Avg Shares Out | 17,432 | 17,303 | 17,303 | 17,640 |
| Weighted Avg Shares Out Dil | 17,432 | 17,303 | 17,303 | 17,640 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $4,800 |
| Interest Expense | $137 | $799 | $819 | $2,469 |
| Depreciation & Amortization | $2,359 | $1,996 | $1,986 | $2,129 |
| EBITDA | -$2,287 | $26,147 | -$1,099 | $15,203 |
| % Margin | -5.5% | 46.4% | -2.8% | 31.4% |